Viking Therapeutics Stock at $37.44 – Analysts See Potential to $101

Viking Therapeutics Inc. (VKTX) stock traded at $37.44 on July 3, 2026, remaining virtually unchanged from the previous day. During the trading session, the stock moved between a low of $36.69 and a high of $38.87, with trading volume of 20,069 shares.

Analysts Broadly Optimistic – Price Target at $93.60

The California-based biopharmaceutical company enjoys high regard among analysts. Of 24 total analyst ratings covered (as of July 4, 2026), 22 issue buy recommendations, with one analyst rating the stock as "Strong Buy." Only one hold recommendation stands against this – there are no sell recommendations.

The average price target is $93.60, with a median of $95.00. The range of analyst estimates spans from a conservative target of $83.00 to an ambitious high of $101.00. Based on the current price, this represents calculated upside potential of approximately 150 percent to the average target.

Technical Indicators Show Intact Upward Momentum

The Relative Strength Index (RSI) for Viking Therapeutics stock stood at 64.84 points on July 2, 2026. The RSI – a momentum indicator measuring overbought and oversold market conditions – between 30 and 70 is typically considered neutral to slightly bullish. The current value signals intact upward momentum without the stock already trading in overbought territory.

In the weeks prior, the RSI repeatedly showed values above 70, such as 75.03 points on June 24 or 75.36 points on June 29. Since the end of June, the indicator has cooled moderately, suggesting a healthy consolidation following a strong upward move.

Company Background: Focus on Metabolic and Endocrine Disorders

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders. The most promising candidate in its portfolio is VK2809, an orally administered selective agonist of the thyroid hormone receptor beta (TRß). The drug is currently in Phase IIb trials for treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Other pipeline candidates include VK5211, a non-steroidal selective androgen receptor modulator (SARM) in Phase II trials for patients post-hip fracture, and VK0612, an oral drug for type 2 diabetes approaching Phase IIb trials. VK0214, another oral agent, is also in development.

Market Capitalization and Fundamental Metrics

At $37.44 and with its current share structure, Viking Therapeutics operates in the mid-cap segment of the biotechnology industry. As a clinical-stage development company without approved products on the market, Viking does not yet have regular revenue streams. Valuation is therefore based primarily on pipeline candidate potential and progress in clinical trials.

Biotech sector investors typically focus on study results, regulatory milestones, and potential partnerships. The optimistic analyst ratings suggest that market observers attribute significant commercial potential to Viking's development candidates.

Trading Activity and Liquidity

Trading volume on July 3, 2026 was 20,069 shares, within the typical range for Viking Therapeutics. The difference between the day's high ($38.87) and low ($36.69) of $2.18 represents a daily range of approximately 5.9 percent – a typical value for biotech stocks, reflecting the higher volatility of this asset class.

The stock trades in USD, which represents currency risk for investors from the DACH region. At a current exchange rate of approximately 0.93 EUR/USD, the $37.44 price equates to roughly €34.82. Currency fluctuations can affect returns in euros or Swiss francs in addition to the stock's own price performance.

Outlook: Study Results as Price Driver

Viking Therapeutics' future price development will likely depend significantly on progress in its clinical programs. In particular, Phase IIb trials of VK2809 for NASH and NAFLD – diseases with high medical need and substantial market potential – are in focus. Positive interim results or successful trial completions could significantly boost the stock, while setbacks would have a correspondingly negative impact.

Broad analyst support with an average price target approximately 2.5 times the current price reflects expectations that at least one pipeline candidate will be successfully brought to market. However, investors should be aware that biotech investments carry substantial risks – clinical trials can fail, regulatory hurdles are high, and capital is tied up for extended periods until potential market launch.